HeartWare Schedules First Quarter Conference Call And Webcast

        HeartWare Schedules First Quarter Conference Call And Webcast

PR Newswire

FRAMINGHAM, Mass., April 22, 2014

FRAMINGHAM, Mass., April 22, 2014 /PRNewswire/ --HeartWare International,
Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial
results for the three months ended March 31, 2014, at 8:00 a.m. U.S. Eastern
Daylight Time on Thursday, May 1, 2014. The Company plans to release the
financial results prior to the conference call.

The conference call with management will discuss the Company's financial
results, highlights from the first quarter and business outlook. The call may
be accessed by dialing 1-877-407-0789 five minutes prior to the scheduled
start time and referencing "HeartWare." For callers outside the U.S., please
dial +1-201-689-8562.

A live webcast of the call will also be available in the Investor section at
the Company's website (http://ir.heartware.com/). A replay of the conference
call will be available through the above weblink immediately following
completion of the call.

A copy of the news release announcing results and related information will be
available on the Company's website, www.heartware.com.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare^® Ventricular Assist
System features the HVAD^® pump, a small full-support circulatory assist
device designed to be implanted next to the heart, avoiding the abdominal
surgery generally required to implant competing devices. The HeartWare System
is approved in the United States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from refractory end-stage
left ventricular heart failure, has received CE Marking in the European Union
and has been used to treat patients in 37 countries. The device is also
currently the subject of a U.S. clinical trial for destination therapy. For
additional information, please visit the Company's website at
www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000^® and its
securities are publicly traded on The NASDAQ Stock Market.

HEARTWARE, HVAD and HeartWare logos are registered trademarks of HeartWare,
Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.

Website: http://www.heartware.com
 
Press spacebar to pause and continue. Press esc to stop.